Indapta Therapeutics is a clinical-stage biotechnology company developing differentiated allogeneic natural killer (g-NK) cell therapies for blood and solid-tumor cancers and autoimmune diseases. Its lead candidate, IDP-023, has completed enrollment in the safety run-in portion of a Phase 1 trial in Non-Hodgkin’s Lymphoma and Multiple Myeloma. In responding myeloma patients the mean maximum decrease in serum M-protein or light chain was 73%, with three patients showing reductions of 84% or greater. Cohorts testing IDP-023 in combination with monoclonal antibodies targeting CD20 or CD38 are currently enrolling. The company secured FDA clearance of an IND to study IDP-023 with ocrelizumab in progressive multiple sclerosis and plans to initiate a Phase 1 MS trial in Q1 2025. Indapta’s proprietary g-NK platform is described as offering multiple mechanisms—enhancing B-cell depletion with antibodies, targeting HLA-E upregulated autoreactive cells, and potentially addressing EBV reservoirs—and the company recently announced a collaboration with Sanofi. It closed a $22.5 million financing to accelerate these clinical development programs. Indapta Therapeutics is a privately held biotechnology company developing a universal, allogeneic NK cell therapy platform based on G-NK cells to treat multiple types of blood cancers and solid tumors. Its G-NK cells are FcεRIγ-deficient, isolated from healthy donors, not genetically engineered, and exhibit increased antibody-dependent cellular cytotoxicity compared with conventional NK cells. Indapta has enhanced G-NK cells through subset selection and a proprietary manufacturing process to produce a banked, off-the-shelf product with reportedly higher efficacy, persistence and improved cryopreservation; in vivo studies have demonstrated safety and efficacy. The company is partnering with Lonza for process development and cGMP manufacturing to support clinical supply. Proceeds from the recent financing will be used to grow the team and advance the G-NK platform toward an IND and clinical trials. Indapta was founded in 2017 based on a discovery at UC Davis, with scientific founders Sungjin Kim and John Sunwoo.

Total raised

$73M

Funding rounds

2

Latest round

Equity

Latest activity

Dec 2024